In this regimen, metastatic tumor cells showed a significant preference for osseous organs (forelimb, hindlimb, spine, skull) when compared to soft tissue organs (liver, kidney, lung, heart, skin), independent of therapy, with most metastatic cells found in the bones of the Ephrin-B2-Fc treatment cohort (Figure 1c). This evidence concerns the gene EFNB2 and neoplasm.